Tanner Pharma Group Initiates a Global Innovative Named Patient Program for Zemdri

Charlotte, NC, May 23, 2023 – Tanner Pharma Group and Cipla Therapeutics Inc. have jointly launched an innovative Named Patient Program (NPP) for Zemdri (plazomicin) Injection.

The collaboration will expand access to Zemdri on a Named Patient basis in countries and regions where the drug is not yet commercially accessible, for patients 18 years of age or older for the treatment of Complicated Urinary Tract Infections (cUTI) including pyelonephritis caused by susceptible microorganism(s): Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Enterobacter cloacae.

Named Patient Program is a mechanism through which physicians can in full compliance with national medical and regulatory standards, legally and ethically prescribe investigational or approved drugs for patients in need, prior to their authorized commercial availability in their countries. Under the terms of the agreement, Tanner will be the supplier of Zemdri to healthcare providers in countries where the drug is not commercially available.

For additional information about Zemdri, please visit Zemdri.com.

About Tanner Pharma Group

Tanner Pharma Group is a specialist pharmaceutical services provider based in Charlotte, North Carolina, USA with offices in Europe and Latin America. Through its Managed Access Programs division, Tanner supports manufacturers by providing ethical, controlled and compliant access to their innovative medicines in countries where they are not commercially accessible. Tanner has been enabling patient access to medicines for more than 20 years in over 130 countries and has extensive experience building and administering Named Patient Programs. Learn more: https://tannerpharma.com/